Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
efficacy including overall response rate, progression free survival and overall survival
According to International Workshop Criteria, the number of participants with complete remission, partial remission and stable disease as a measure of efficacy.progressive free survival and overall survival of the participants are the second measure of efficacy
1 year
Yes
Huaqing wang, MD
Principal Investigator
Tianjin Medical University Cancer Institue and Hospital
China: Food and Drug Administration
2367240
NCT01430013
June 2011
June 2014
Name | Location |
---|